IBRX Latest Headlines

ImmunityBio (IBRX) Gets a Buy from BTIG

at www.tipranks.com (Tue, 10-Nov 6:16 AM)

ImmunityBio Says ANKTIVA Plus BCG Hit the Primary Endpoint in a 370-Patient QUILT-2.005 Bladder Cancer Trial

Market Chameleon (Mon, 9-Nov 9:54 AM)

Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and ImmunityBio (IBRX)

at www.tipranks.com (Mon, 9-Nov 2:20 PM)

ImmunityBio GAAP EPS of -$0.18 misses by $0.10, revenue of $48.84M misses by $10.39M

at seekingalpha.com (Mon, 9-Nov 7:39 AM)

ImmunityBio Reports Positive ANKTIVA Bladder Cancer Trial Results

at www.tipranks.com (Mon, 9-Nov 6:59 AM)

ImmunityBio says first European patients have been treated with ANKTIVA plus BCG following February 2026 EU conditional authorization

Market Chameleon (Wed, 4-Nov 9:08 AM)

ImmunityBio sets November 2026 topline timeline after database lock in 366-patient ANKTIVA plus BCG bladder-cancer trial

Market Chameleon (Wed, 21-Oct 8:14 AM)

ImmunityBio Highlights 84% Cystectomy Avoidance at Three Years in Long-Term ANKTIVA Plus BCG Follow-Up

Market Chameleon (Mon, 19-Oct 11:38 AM)

IBRX gains broader access for ANKTIVA as FDA label expands to papillary-only NMIBC, a group representing about 85% of patients

Market Chameleon (Thu, 15-Oct 7:09 AM)

ImmunityBio Taps Founder Patrick Soon-Shiong for an Oct. 16 Piper Sandler Oncology Fireside Chat

Market Chameleon (Fri, 9-Oct 11:37 AM)

ImmunityBio (IBRX) highlights ANKTIVA progress ahead of an Oct. 16 Piper Sandler fireside chat

Market Chameleon (Thu, 8-Oct 8:46 AM)

IBRX’s eight straight quarters of ANKTIVA revenue growth puts commercial execution at center stage

Market Chameleon (Mon, 5-Oct 7:31 AM)

IBRX Rises as Director Linda Maxwell Adds Another Board Seat After HLS Appointment

Market Chameleon (Fri, 2-Oct 11:36 AM)